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Abstract 
In the present study, a functional neuron restrictive silencer element (NRSE) was 
initially identified in the 5’ flanking region (-83 to -67, relative to ATG) of human 
secretin receptor (hSCTR) gene by promoter assays coupled with scanning mutation 
analyses. The interaction of neuron restrictive silencer factor (NRSF) with this motif 
was later indicated via gel mobility shift and ChIP assays. The silencing activity of 
NRSF was confirmed by over-expression and also by shRNA knock-down of 
endogenous NRSF. These studies showed an inverse relationship between the 
expression levels of NRSF and hSCTR in the cells. As hSCTR gene was previously 
shown to be controlled by two GC-boxes which are regulated by the ratio of Sp1 to 
Sp3, in the present study, the functional interactions of NRSF and Sp proteins to 
regulate hSCTR gene was investigated. By co-immunoprecipitation assays, we found 
that NRSF could be co-precipitated with Sp1 as well as Sp3 in PANC-1 cells. 
Interestingly, co-expressions of these factors showed that NRSF could suppress 
Sp1-mediated, but not Sp3-mediated, transactivation of hSCTR. Taken together, we 
propose here that the down-regulatory effects of NRSF on hSCTR gene expression are 
mediated via its suppression on Sp1-mediated transactivation. 
 
Keywords: secretin receptor, neuron restrictive silencer factor, Sp-protein, 
transcriptional regulation. 
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1. Introduction 
Secretin (SCT), a brain-gut peptide belonging to the secretin/vasoactive intestinal 
peptide/glucagon peptide family, functions to stimulate secretion of bicarbonate, 
electrolytes and water from pancreatic ductal epithelial cells [1], while its effects on 
other gastrointestinal tissues including intestine [2], stomach [3] and liver [4] were 
also suggested. Recently, the neuroactive functions of secretin were studied. It was 
suggested that in the cerebellum, secretin acts as a retrograde messenger to facilitate 
GABA release from the presynaptic basket cells, either directly or indirectly via an 
unknown glutamate source, resulting in potentiating evoked inhibitory postsynaptic 
currents (IPSCs) in Purkinje cells [5,6]. Recent evidences have suggested that SCT is 
potentially a neurohypophysial factor [7]. SCT and its receptor (SCTR) overlap with 
the functions of angiotensin II (ANGII), and more importantly, are needed in 
mediating the central actions of ANGII-induced responses [8]. 
The activities of secretin are mediated via a class II G protein-coupled receptor, 
secretin receptor (SCTR). Using human pancreatic ductal carcinoma (PANC-1) and 
bovine pancreatic ductal (BPD-1) cells as models, we have previously identified a 
106-bp core promoter element (-263 to -158, relative to the ATG start codon) in the 5’ 
flanking region of the human secretin receptor (hSCTR) gene [9]. This core promoter 
is controlled by the competitive binding of specificity protein 1 and 3 (Sp1 and Sp3) 
with two functional GC boxes (-240 to –226 and –203 to –194).  In addition, the 
methylation status of CpG dinucleotides in the CpG island which overlaps with the 
core promoter was also found to be a critical factor to mediate the cell-specific 
expression of the hSCTR [10]. 
To understand further the spatial and temporal expression of hSCTR, in this 
report, we sought to investigate the functions of a putative neuron restrictive silencer 
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element (NRSE) located downstream (-83 to -67, relative to ATG) of the hSCTR core 
promoter. NRSE, also known as repressor element-1 (RE-1) with a consensus 
sequence “NTYAGMRCCNNRGMSAG” [11], was initially identified to regulate a 
number of neuron-specific genes by repressing their expressions in non-neural tissues 
[12]. Recently, NRSE is regarded a common repressor element as it can suppress an 
increasing number of non-neuronal genes. A genome-wide search indicated the 
presence of about 1,800 putative NRSE sites in both human and mouse genomes [11]. 
The protein factor that interacts with NRSE is neuron-restrictive silencer factor 
(NRSF), which is a member of the zinc-finger GLi-Krüppel family [13]. There are 
three domains in NRSF: a Krüppel-type zinc-finger for binding NRSE, an N-terminal 
repressor domain for interacting with SIN3 transcription regulator (Sin3), and a 
C-terminal repressor domain for recruiting the corepressor element 1 silencing 
transcription factor (CoREST). Both Sin3 and CoREST interact with histone 
deacetylase containing complex to deacetylate core histone proteins, and as a 
consequence, they work together to silence target genes by forming condensed 
chromatin structures and mediates developmental stage-specific gene expression 
[14,15,16]. An in silico analysis indicates that all members of the secretin receptor 
family contain at least one putative NRSE-like motif in their 5’ flanking regions [17]. 
With the knowledge that most of NRSF-regulated genes also possess GC-boxes in 
their promoter regions [18,19], for this reason, the functional relationships between 
Sp-protein(s) and NRSF in controlling hSCTR expression was investigated. Findings 
reported here not only provide crucial information regarding the cell-specific 
expression of hSCTR, but also are applicable to the understanding of other 
GC-box/NRSF co-regulated genes, including several members of the secretin receptor 
family. 
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2. Materials and Methods 
2.1 Cell culture 
All cell lines were purchased from American Type Culture Collection (ATCC). 
PANC1-1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, 
Invitrogen, Carlsbad, CA) with 10% FBS. PC12 cells were cultured in DMEM with 
10% horse serum and 5% fetal bovine serum (FBS). All cells were cultured at 37°C 
with 5% CO2 in a medium supplemented with 100 U/ml penicillin G and 100 µg/ml 
streptomycin (Invitrogen). 
 
2.2 Plasmid construction 
Cloning of the hSCTR promoter was described previously [9]. The plasmid 
p263/158 (–263 to –158 relative to the ATG start codon) was generated by 
exonuclease III/S1 nuclease digestion (Amersham Pharmacia, Arlington Heights, IL) 
followed by cloning into the Mlu I/Xho I sites of the pGL-2 basic vector (Promega 
Corp, Madison, WI). The region -263/-46 was obtained by PCR amplification of 
human genomic DNA and then subcloned into the Mlu I/Xho I sites of the pGL2 basic 
vector (Stratagene, La Jolla, CA). Expression vectors, Sp1/CMV. Sp3/CMV and 
Sp4/CMV were kindly provided by Prof. C. Paya (Mayo Clinic, Rochester, US). The 
NRSF expression vector, REEX1/CMV, and the dominant negative expression vector, 
p73/CMV, were gifts from Dr. Mandel (State University of New York) [20]. The 
potential shRNA target sites of human NRSF was determined using the Ambion 
design program (Ambion, CA), and the sequences were BLAST-confirmed for 
specificity. Sense and antisense oligos were annealed in an annealing buffer (100 mM 
potassium acetate, 30 mM HEPES (pH 7.4) and 2 mM magnesium acetate) at 90°C 
for 3 min, followed by incubation at 37°C for 1 h. The annealed DNA was cloned into 
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the Apa I/Hind III sites of pSilencer 1.0-U6 shRNA expression vector (Ambion) for 
constructing shNRSF vector. As a negative control, siControl (Ambion) with a 
sequence that shares no significant identity to any known gene sequence was used. 
 
2.3 PCR-linker Scanning Mutagenesis 
Site-directed mutagenesis was carried out by a three-step PCR method (Nelson 
& Long 1989), using mutagenic primers MA, MB, MC, MD, ME, M1, M2 or DM 
and universal primers GL2-MP, GL1 and MP (Table 1). The region –263/-158 was 
initially subcloned into Mlu I/Xho I sites of pGL2, and this construct was used as a 
template for all PCR mutagenesis. Mutations introduced were subsequently confirmed 
by DNA sequencing. 
 
2.4 Transient transfection assay 
PANC-1 and PC12 cells were plated at a density 2.5 x 105 cells / 35 mm well 
(six-well plate, Costar). After 2 days incubation, promoter-luciferase construct and 
β-gal control vector were cotransfected into cells using the Genejuice reagent 
(Novagen, Darmstadt) according to the manufacturer’s protocol. Cells were harvested 
48 h after transfection and cell extracts were assayed for luciferase and 
β-galactosidase activities as described previously [21]. For in vitro functional studies, 
2 days after plating, promoter constructs and various amounts of the expression vector 
(Sp1/CMV, Sp3/CMV, Sp4/CMV, REEX1, and p73) and/or shRNA vector in a total 
of 3.5 µg DNA (adjusted by pBluescript KS+) were cotransfected into cells by 
Genejuice reagent. The transfected cells were incubated for two more days before 
luciferase and β-galactosidase activities were determined. 
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2.5 Co-immunoprecipitation and gel mobility shift assay 
PANC-1 nuclear extract was prepared as described before [22], and was 
incubated with 2 µg of the appropriate antibodies (NRSF, Sp1, Sp3 and Sp4, Santa 
Cruz Biotechnology, CA) for 2 h at 4oC. Protein G-agarose beads (20 µl) were used to 
pull-down the Ab-Ag complex. Western blotting was performed essentially according 
to a protocol described earlier [23]. The presence of NRSF in the nuclear extract was 
visualized by the ECL system (Amersham Biosciences, Buckinghamshire, UK). For 
gel mobility shift assays, double-stranded oligonucleotide probes (DNA sequences 
listed in Table 1) were end-labeled with [γ-32P] by the Ready-To-Go 
T4-polynucleotide kinase labeling kit (Amersham Biosciences). Gel mobility shift 
assays were carried out at room temperature for 20 min in a 20 µl reaction mixture 
containing 10 mM Tris (pH 7.5), 50 mM NaCl, 2.5 mM MgCl2, 0.5 mM dithiothreitol, 
4% glycerol, 2 µg poly(dI:dC) (Amersham Biosciences) and 1 pmole probe. Free and 
bounded probes were separated by electrophoresis in a 5% polyacrylamide gel. For 
competition assays, a graded concentration of unlabeled DNA was added with the 
labeled probe. In the supershift assay, antibody against NRSF (sc-15118X) or 
AP-2 (sc-8975X) (Santa Cruz Biotechnology) was included in the reaction mix. 
 
2.6 Chromatin immunoprecipitation (ChIP) assay 
The ChIP assays were performed essentially according to Baek et al. [24].  
PANC-1 cells were cross-linked with 1% formaldehyde for 15 min at room 
temperature. Cells were harvested by centrifugation and resuspended in the lysis 
buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.1, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 µg/ml Aprotinin and 1.5 µg/ml Pepstatin A). After sonication in 
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Sonifier 450 (Branson, Danbury, CT), 10 µg antibody and 20 µl Protein A/G plus 
agarose were added to precipitate the DNA-protein complex. Precipitated 
DNA-protein complex was washed in the ChIP buffer (0.1% SDS, 1% Triton X-100, 
0.1% Na deoxycholate, 140 mM NaCl , 1 mM PMSF, 1 µg/ml Aprotinin and 1.5 
µg/ml Pepstatin A) and eluted in the elution buffer (1% SDS and 0.1 M NaHCO3). 
The mixture was incubated at 65°C for 4 h to reverse the formaldehyde cross-linking. 
Proteins were digested by proteinase K (200 µg/ml) at 45°C for 2 h and followed by 
phenol/CHCl3 extraction. The extracted DNA was used for PCR using the primers 
showed in Table 1. For real-time PCR analysis, the extracted DNA was amplified by 
the SYBR Green PCR Master Mix kit (Applied Biosystems, Foster City, CA) and the 
signal was detected by the iCycler iQ detection system (Bio-Rad, Hercules, CA). The 
percentage recovery was normalized by the Ct value from the input control. 
 
2.7 Real-time quantitative reverse-transcription polymerase chain 
reaction (RT-PCR) analysis 
Total RNAs from cells were isolated using the TriPure reagent (Roche Molecular 
Biochemicals, Switzerland) and reverse-transcribed (5 µg) by an oligo-dT primer and 
Superscript III (Invitrogen). One-tenth of the first strand cDNAs was used for 
real-time PCR analysis, in which secretin and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) levels were measured by an Assays on Demand System (ID: 
Hs00161610_m1; Applied Biosystems) or Pre-developed Taq-man probe with the 
Taqman Universal Master Mix (Applied Biosystems) using the iCycler iQ detection 
system (Bio-Rad). Relative expression levels of transcripts were calculated by the 
2-ΔΔCt method [25] using GAPDH as the endogenous control. 
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2.8 Data analysis 
Data from the transfection assays were shown as the means ± SEM of triplicate assays 
in at least three independent experiments. Data from quantitative PCR were shown as 
the means of ± SEM of duplicate assays in at least three independent experiments. All 
data were analyzed by one-way ANOVA and followed by Dunnett’s test using the 
computer software PRISM (version 3.0, GraphPad Software Inc., San Diego, CA). 
 
3. Results 
3.1 Identification of a functional NRSE in the 5’ flanking region of the 
hSCTR gene 
In human and mouse SCTR genes, putative NRSE sites at -83/-67 and -314/-298, 
respectively, relative to the ATG codon were identified (Figure 1A). To initially 
investigate whether this motif is functional in hSCTR, several DNA fragments with 
different 3’ regions (ranged from -158 to -1) were linked to the luciferase reporter 
gene for transient promoter assays using the human pancreatic PANC-1 cell as a 
model. Constructs with the core promoter and the putative NRSE (p-263/-45, p-263/-1) 
exhibited promoter activities significantly lower than that of the control (core 
promoter construct p-263/-158) (Figure 1B). To locate the repressor/silencer element, 
scanning mutants (MA to ME Figure 1C) were constructed, and among them, changes 
of NRSE sequences led to either complete or partial recovery in promoter function 
(MD: 101%; ME: 79% vs control p-263/-158). The importance of NRSE was then 
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confirmed by mutating the core nucleotides [11] of the motif (Figure 1D). In this 
study, mutation of either 1 or 2 core nucleotides resulted in partial but significant 
recovery of promoter activities (M1: 49% recovery, M2: 71%, and DM: 56%). Taken 
together, the conserved NRSE is a functional motif that down regulates the hSCTR 
gene expression. 
 
3.2 In vitro and in vivo interaction of NRSF with NRSE in the hSCTR 
gene 
 To identify the transcription factor(s) that interacts with the NRSE, initially, gel 
mobility shift assays were performed. Using an NRSE-I oligo, two specific 
DNA-protein complexes were observed in PANC-1 nuclear extract (complexes A and 
B, Figure 2A, lanes 2 to 4). These complexes were specific as only cold NRSE-I or 
NRSE consensus (rM4RE1) [11,26,27], but not non-specific oligo, could abrogate 
their formation (Figure 2B). Consistently, as shown in supershift assays, addition of 
NRSF antibody reduced the intensities of these complexes (Figure 2C, lane 3) while 
the addition of an un-related AP2 antibody or non-specific bovine serum albumin 
(BSA) was ineffective in supershifting these complexes (Figure 2C, lanes 4 and 5). 
To show the in vivo binding of NRSF to NRSE, ChIP assays (from -263 to -45) 
were performed (Figure 2D). In this study, we observed no PCR signals from the 
negative controls (anti-rabbit IgG, lane 3; No immunoprecipitation, lane 5; and PCR 
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negative, lane 6), indicating that there were neither non-specific precipitations nor 
PCR contamination. Positive PCR signals were detected only when NRSF antibody 
was used (lane 4, sample; lane 2, positive control). Moreover, by amplifying the exon 
3 to intron 4 sequence of hSCTR as the control, there are no positive signal was 
observed in all antibody precipitation, including the NRSF antibody. This further 
confirmed the specificity of the ChIP assay. Similar results were also observed in 
ChIP-real time PCR assay (Figure 2E). NRSF immunoprecipitation shows strongest 
signal (with 34% recovery) when compare to IgG and No IP control (<5% recovery). 
In summary, gel mobility shift assays and ChIP assays showed the in vitro and in vivo 
interaction of NRSF with the hSCTR promoter. 
 
3.3 Transcriptional down-regulation of hSCTR gene by NRSF 
To investigate the in vivo roles of NRSF to repress hSCTR expression, an NRSF 
expression vector (REEX1) [20] was cotransfected with the NRSE-containing 
promoter construct p-263/-45 into PC12 cells. We used PC12 cells as these cells do 
not express endogenous NRSF [28]. 
 As shown in Figure 3A, over-expression of NRSF caused a significant and 
dose-dependent decrease in hSCTR promoter activity in PC12 cells. The hSCTR 
promoter activity was decreased 53% when 2.0 µg of REEX1 was transfected into 
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PC12 cells. In the hSCTR expressing PANC-1 cells, over-expression of NRSF also 
led to a significant drop in hSCTR transcript levels (Figure 3B).  By real-time 
RT-PCR, a 64% decrease of hSCTR mRNA was observed when 2.0 µg NRSF vector 
was transfected into the cells. These data therefore confirmed that an increased 
expression of NRSF could down-regulate hSCTR promoter, leading to reduced in vivo 
transcript levels of hSCTR.  
To better reflect the in vivo actions of NRSF, we sought to knock-down 
endogenous NRSF by a vector-based shRNA approach. The knock-down effect of the 
shRNA (shNRSF) on NRSF expression level was confirmed by Western blotting 
(Figure 3E). As shown in the figure, the increase of shNRSF vector in the transfection 
can significantly reduce the protein level of NRSF in the transfected PANC-1 cells. 
By cotransfecting shNRSF with the promoter constructs, a significant augmentation 
of luciferase activity was observed only in the NRSE-containing promoter (p-263/-45: 
2.7-fold against control with no shNRSF, Figure 3C), but not in the core promoter 
(p-253/-158). Finally, we found also that the shNRSF vector could up-regulate 
endogenous hSCTR expression (Figure 3D: 3.8-fold increase in hSCTR transcript 
level). In summary, changes in NRSF concentrations in PANC-1 cells could 
oppositely regulate hSCTR expression and this effect is mediated by the NRSE 
cis-acting motif located at the 5’ region of the hSCTR gene. 
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3.4 NRSF-mediated transcriptional down-regulation is Sp1 dependent 
As it has previously been shown that hSCTR is controlled by the Sp1/Sp3 ratio 
[10] and the repressor effects of NRSF is mediated via inhibition of Sp1 [18], we 
therefore investigated the potential interactions of NRSF and Sp-proteins in regulating 
hSCTR promoter in PANC-1 cells. To show the physical contact of Sp-proteins with 
NRSF on hSCTR promoter, we performed co-immunoprecipitation assays. As shown 
in Figure 4A, NRSF co-immunoprecipitated with Sp1 and Sp3 antibody and provided 
strong signals in the Western blot. Consistently, the NRSF-immunoprecipitated 
proteins contained also Sp1 and Sp3 as shown in the Western blots (Figure 4B, C). 
These data showed the endogenous interactions of NRSF with Sp1 and Sp3 in 
PANC-1 cells, although we cannot prove that these interactions are hSCTR-promoter 
specific. The next series of experiments were then designed to test the in vivo 
functional interactions of Sp1 and Sp3 with NRSF. By over-expressing Sp1, Sp3 or 
Sp4 with p-263/-45 (Figure 5A), we found that, Sp4 consistently had no effect, while 
both Sp1 and Sp3 could activate the NRSE-containing promoter. More interestingly, 
the activities of Sp1 and Sp3 in the NRSE containing promoter were different from 
our previous [10] and also present (Figure 5D) studies with the core promoter (-263 to 
-158). When the core promoter was used, Sp1 was a stronger activator comparing 
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with Sp3 (Figure 5D, Sp1: 2.5-fold vs Sp3: 1.2-fold, respectively). However, when 
the NRSE-containing promoter was employed, Sp3 was a stronger activator on 
promoter activity (Fig 5B, Sp3: 3.7-fold vs Sp1: 2.2-fold). These data suggest 
differential functions of Sp1 and Sp3 in controlling hSCTR expression in the presence 
or absence of NRSF. 
To investigate the mechanisms underlining the differential activities Sp1 and Sp3, 
we co-expressed Sp1 or Sp3 with NRSF or a dominant negative NRSF p73 [20] 
(Figure 5B). NRSF over-expression significantly reduced the Sp1-mediated activation 
(from 219% to 60.3% against p-263/-45), whereas over-expression of the dominant 
negative NRSF p73 had no effect (Fig 5B). On the contrary, the Sp3-mediated 
transactivation was not significantly affected by NRSF or p73 (Fig 5B: lanes 7-9). To 
confirm these observations, shNRSF was used to knockdown the endogenous NRSF 
in PANC-1 cells in normal and Sp-protein over-expressed conditions. In the absence 
and presence of Sp1, silencing of endogenous NRSF could up-regulate hSCTR 
promoter activity (Fig 5C: lanes 1-6), while shNRSF seemed to exhibit no effect in 
Sp3-over-expressed cells (Fig 5C: lanes 7-9). As a control, over-expressing or 
silencing of endogenous NRSF had little effects on the core-promoter without the 
NRSE (Figure 5D).  Taken together, our data suggested that the differential 
functions of Sp1 and Sp3 is a result of the specific inhibition of NRSF on 
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Sp1-mediated transactivation in the hSCTR promoter.  It was previous reported that 
NRSF could recruit histone deacetylases (HDAC) to repress gene expression through 
chromatin remodeling. In this study, when a HDAC inhibitor (Trihostatin A, TSA) 
was employed, hSCTR promoter (-263/-45) activity was significantly increased in 
Sp1- (1.8-fold increase), but not Sp3-transfected cells (Figure 6). In the control 
experiment, when the NRSE motif was removed from the promoter (DM), the TSA 
treatment did not show significant effects on the promoter activities after either Sp1 or 
Sp3 oeverexpression. Our present data, taken together, therefore suggest that NRSF, 
via its interactions with Sp1 and HDAC, functions to repress hSCTR gene. 
 
4. Discussion 
4.1 NRSF and cell-specificity of secretin receptor 
Secretin receptor waspreviously considered to be localized to classical sites such 
as the pancreatic and biliary ductal cells. Now it has been demonstrated that secretin 
receptors are expressed in specific cell types in various parts of the brain [5,29,30] as 
well as peripheral tissues [31.32,33]. The spatial and temporal regulation of this 
receptor is the key to understanding secretin’s physiology, but remains largely 
unknown. The present study provides new information regarding the transcriptional 
mechanisms controlling SCTR gene involving NRSF. NRSE was originally found in 
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the 5’ flanking region of the gene encoding the voltage-gated sodium type II channel 
[34]. NRSF silences NRSE-containing genes in a cell-specific manner and it is 
expressed in many cells except mature neurons and pancreatic β-cells [28]. NRSF are 
reported to regulated many G-protein coupled receptors, such as GPR10 [35], 
metabotropic glutamate receptor 1 [36], mu opioid receptor [37, 38], and AMPA 
glutamate receptor subunit GluR2 [39]. 
In the present study, we demonstrated the repressor effects of NRSF by binding 
onto the NRSE motif (-83 to -67, hSCTR gene), hence, we proposed here that this 
mechanism could be responsible for the suppression of SCTR gene in 
SCTR-expressing and non-SCTR expressing cells. In this study, we have used the 
hSCTR-expressing PANC-1 cell [9,10] that also expresses NRSF (Western blotting, 
data not shown). As previous studies [13,20,40], a threshold level of NRSF is required 
for complete silencing of transcription. As shown here, overexpression of NRSF 
could still reduce hSCTR, suggesting that the endogenous NRSF level in PANC-1 
cells is not sufficient to completely silence the hSCTR gene. In summary, in 
NRSF-expressing PANC-1 cell, the endogenous NRSF level is therefore a key factor 
in controlling SCTR expression. 
Other than the well known gastrointestinal functions of SCT, our recent data also 
suggested that SCT is potentially a neurohypophysial factor [7] and it is an important 
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central regulators in osmoregulation [8] and appetite control [41]. We showed that the 
SCTR is expressed in hypothalamus, including the arcuate nucleus (Arc), supraoptic 
nucleus (SON) and paraventricular nucleus (PVN) [8, 41]. It is interested to note that 
the expression of NRSF is lower in brain, hypothalamus and pancreatic islets [42]. 
The contrary expression pattern between SCTR and NRSF further suggests the role of 
NRSF in down-regulating the SCTR. It has been shown that the expression of 
corticotropin-releasing hormone can be reprogramed by the NRSF expression in 
stress-responsive hypothalamic neurons [43]. Recently, we found that the expression 
of SCT in hypothalamus was up-regulated by hypertonicity and angiotensin II 
stimulation [44]. Therefore, the expression of hSCTR may be regulated by similar 
stimulation through the NRSF in hypothalamus and in other tissues. 
 
4.2 Mechanism of NRSF’s repressor activity on secretin receptor gene 
Recent studies have suggested that the transcriptional repression mediated by 
NRSF is Sp1-dependent [18]. In our previous works, we showed that Sp1 is a 
predominant activator, whereas Sp3, itself a weak activator, inhibits hSCTR 
expression by competing with Sp1 for the same binding sites [10]. As Sp1/Sp3 ratio 
varies in different cells and also at different stages of the cell cycle [45,46], our data 
indicate the importance of the stochastic ratio of Sp1 and Sp3 in the control of hSCTR 
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gene expression. In the present study, we provided evidence that NRSF could 
specifically down-regulate Sp1-mediated transactivation. Our data clearly suggested 
that NRSF interacts with both Sp1 and Sp3 (Figure 4). Hence, the specificity of NRSF 
on Sp1 is not likely due to differential interactions. Actually, in a TATA-less 
promoter such as the hSCTR promoter, Sp1 facilitates binding of transcription factor 
IID (TFIID) to recruit factors for forming the preinitiation transcriptional complex 
[47,48,49]. It is possible that interactions of NRSF with Sp1 could block the binding 
of Sp1 with other transcriptional-associated proteins and finally prevent the formation 
of the preinitiation complex. Alternatively, it has been reported that HDAC could 
interact with Sp1 to form a silencing complex [50]. Since NRSF recruits HDAC via 
both the C- and N- termini through Sin3 or CoREST, NRSF could enhance formatting 
of the silencing complex for histone deacylation or gene silencing [18]. Meanwhile, 
treatment of an HDAC inhibitor, TSA, relieves the down-regulation of NRSF to Sp1 
[40], suggesting that HDAC is key to the silencer activity of NRSF. 
Our data also indicated a specific role of Sp1, but not Sp3, in linking NRSF with 
HDAC in changing the local chromatin structure for transcriptional down regulation. 
This observation is consistent with previous reports showing that a direct interaction 
of Sp3 and HDAC could not be detected in the two-hybrid system [51]. The 
difference between the interactions of Sp1 and Sp3 with HDAC may be the key to 
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understand the differential actions of these Sp-proteins on SCTR gene, as well as the 
secretin receptor super-family expression. 
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Figure Legends 
Figure 1. A putative NRSE represses the hSCTR promoter activity. (A) Sequence 
comparison of NRSE motifs in human and mouse SCTR with NRSE consensus 
sequence. Conserved nucleotides were highlighted in bold letters. Nucleotides which 
are necessary for NRSF functions are underlined. Position numbers are relative to the 
ATG start codon of SCTR. (B) The hSCTR core promoter with different 3’ extension 
were inserted into the pGL-2 basic vector. Luciferase activities are normalized by 
β-galactosidase expression and are shown as the fold increases in relative promoter 
activities compared with the empty vector, pBasic (pGL-2 basic). (C) Scanning 
mutation analysis of the region (-113/-57). Upper panel: DNA sequences of the region 
(-113/-57), and the underlined sequences are the sites of the scanning mutations (MA–
ME). The sequences in the open box represent the putative NRSE site. Lower panel: 
A family of 6-bp block mutants were constructed and used for transient promoter 
assays. The boxes with a cross inside are the mutated sites. (D) Mutation Analysis of 
the NRSE (-83/-67) site. Two mutants with 4-bp block replacement (M1-M2) and the 
double mutants (DM) were constructed and used for transient promoter assays. The 
DNA sequences of NRSE (-83/-67) were shown and the underlined sequences are the 
sites of mutations. Luciferase activities are normalized by β-galactosidase activity and 
are shown as the percentage change in relative promoter activities compared with that 
in core promoter (-263/-158). Values reported in the figure represent the means ± 
SEM of three independent experiments, each in triplicate. *, (P < 0.001 and **, P < 
0.05). 
 
Figure 2. In vitro and in vivo interaction of NRSF with hSCTR promoter. (A) Gel 
mobility shift assays using PANC-1 nuclear extracts and NRSE-I oligo. Different 
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amounts of nuclear extract (ranged from 5 to 15 µg, lane 2 - 4) were incubated with 
the labeled NRSE-I probe. Arrows indicate specific DNA-protein complexes. (B) 
PANC-1 nuclear extract (15 µg) was pre-incubated with the competitor (NRSE-I or 
non-specific oligo; lanes 3 - 6) or NRSE consensus oligo (rM4RE1, lanes 7 - 8). (C) 
Supershift assays. PANC-1 nuclear extract (15 µg) was pre-incubated with an 
antibody (2 µg; lanes 3 - 4) specific for NRSF or AP2. BSA was used as a negative 
control. (D) ChIP assay shows in vivo binding of NRSF to hSCTR promoter. 
Chromatin from PANC-1 cells was crosslinked, and immunoprecipitated with 
anti-NRSF antibody (lanes 4), and used for PCR. Upper: A 194-bp fragment 
containing the NRSE region of the hSCTR promoter is observed. Immunoprecipitation 
without an antibody (No IP, lane 5) and with a non-specific antibody against rabbit 
IgG (IgG, lane 3) were carried out as negative controls. Lane 6, PCR negative control 
(without DNA). Input DNA from fragmented chromatin prior to immunoprecipitation 
was used as a positive control (lane 2). Lane 1, DNA size standards (100-bp DNA 
ladder; Invitrogen). Lower: PCR of a 381-bp fragment flanking the exon 3 to intron 4 
of hSCTR was used as the control. Only the input DNA (lane 1) shows positive signal. 
No PCR product was found in all the immunoprecipitation samples and negative 
controls, including the NRSF (lane 4). (E) Real-time PCR analysis of NRSF ChIP 
assay. After immunoprecipitation, the hSCTR gene promoter was amplified by 
real-time PCR. N.D., not detectable. 
 
Figure 3. Effects of NRSF on hSCTR expression. (A) Overexpression of NRSF in 
PC12 cells down-regulated the hSCTR promoter activity. p-263/-45 was cotransfected 
with various amounts of NRSF-expression vectors (REEX1) into NRSF-deficient 
PC12 cells. Total DNA amount was adjusted to 4 µg by pBluescript KS+ DNA. 
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Luciferase activities are normalized by protein concentrations and are shown as the 
percentage increases in relative promoter activities compared with that of the control. 
Values reported represent the means ± SEM of at least three independent experiments, 
each in triplicate. * and ** indicate significant difference (P < 0.001, P < 0.05) from 
p-263/-45 without REEX1. (B) Overexpression of NRSF decreased hSCTR transcript 
levels in PANC-1 cells. REEX1 (1 or 2 µg) transfected into PANC-1 cells were used 
for real-time PCR. The hSCTR mRNA / GAPDH mRNA ratio was calculated by the 
2-ΔΔCt method. The mRNA level in the control (no REEX1) is defined as 1.0. Data 
represent the means ± SEM of three experiments performed in duplicates. **, P < 
0.05 vs control. (C) Activity of a NRSE-containing promoter (p-263/-45) was 
up-regulated by cotransfection of shNRSF. Constructs (p-263/-158 or p263/-45) were 
cotransfected with either pSilencer empty vector or shNRSF construct (2 µg) into 
PANC-1 cells. Luciferase activities are normalized by β-galactosidase activity and are 
shown as the percentage changes in relative promoter activities compared with that in 
the core promoter (-263/-158). Values reported in the figure represent the means ± 
SEM of three independent experiments, each in triplicate. *, P < 0.001. (D) shNRSF 
vector increased endogenous hSCTR transcripts in PANC-1 cells. The hSCTR 
mRNA/GAPDH mRNA ratio was calculated by the 2-ΔΔCt method. The mRNA level 
in the control (pSilencer) is defined as 1.0. Data represent the means ± SEM of three 
experiments performed in duplicates. *, P < 0.001 vs control. (E) Effects of silencing 
endogenous NRSF by shNRSF. shNRSF-1 (0.5, 1.0 and 2.0 µg), empty vector 
(pSilencer) and generic gene-targeting siControl were used as controls were 
transfected into PANC-1 cells. Left, Western blot analysis of NRSF protein in 
PANC-1 cells transfected with (1) pSilencer, (2-4) shNRSF (0.5 - 2.0 µg) and (5) 
siControl. Right, Coomassie blue staining of a SDS-PAGE run in parallel as a loading 
control. 
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Figure 4. NRSF interacts with Sp1 and Sp3. (A) Sp proteins were immunoprecipitated 
using 0.5 mg total cell lysate from NRSF-expressing PANC-1 cells. The proteins 
were separated by 8% SDS-PAGE and NRSF was detected by Western blotting using 
the NRSF antibody. (B and C) Total cell lysate (0.5 mg) was immunoprecipitated 
with NRSF antibody. Samples were separated by 10% SDS-PAGE and the presence 
of (B) Sp1 or (C) Sp3 was detected by the corresponding antibodies. Loading controls 
were done by Coomassie blue staining of SDS-PAGE (Data not shown). 
 
Figure 5. Effects of Overexpressing Sp1, Sp3 and Sp4 on hSCTR Promoter (-263 to 
-64) in PANC-1 Cells. (A) p-263/-64 was cotransfected in the absence and in the 
presence of 0.5 or 1 µg of Sp1, Sp3 or Sp4 vector. (B) Effects of overexpressing Sp 
proteins in the presence of NRSF. p-263/-64 and NRSF or DN-NRSF were 
cotransfected with Sp1 or Sp3 vector. (C) Cotransfection of p-263/-64 with shNRSF 
and Sp1 or Sp3. (D) The core promoter (p-263/-158) was cotransfected with Sp1 or 
Sp3 vector in the presence of shNRSF or NRSF. Luciferase activities are normalized 
by protein concentrations and are shown as the percentage increases in relative 
promoter activities compared with that in the control (p-263/-158 or p-263/-45 alone). 
Values reported represent the means ± SEM of three independent experiments, each 
in triplicate. *, P < 0.001 vs p-263/-158 or p-263/-45. 
 
Figure 6. Sp1 increased hSCTR promoter activity in TSA-treated cells. PANC-1 cells 
were transfected with p-263/-45 or p-263/-45(DM) in the presence of Sp1 or Sp3 
vector. The cells were then treated with 100 nM TSA for 24 h. Relative luciferase 
activities were expressed in percentage changes against control (no TSA and no 
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Sp-protein). Values reported in the figure represent the means ± SEM of three 
independent experiments, each in triplicate. *, P < 0.001 vs control.  
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Name Oligonucleotide (5’ to 3’) 
Site-directed mutagenesis 
MA  GCAGCGGCCGGCATTCTACCGGGACCCTGC 
MB  GGCCGGAGCCCGTTCAAATGCGCGGGGCGC 
MC  CCGGGACCCTGCTATTTTCGCTGAGCTCCC 
MD  CAGCTCGAGCGCTCGGGCTAGACGCGCCCCGCGCA 
ME  CTCGGGGCGCAGATTATTGCCGGAGCCCG 
M1 CAGCTCGAGCGCTCGGGAGCTCCTTCCCCCGCGCAGGGTCC 
M2 CAGCTCGAGCGCTCGGGAGCTCAGCGCCCCCCGACTGGTCCCGGGCTC 
DM CAGCTCGAGCGCTCGGGAGCTCCTTCCCCCCCGACTGGTCCCGGGCTC 
ChIP assay 
-45-R TCGCTCGAGCGCTCGGGAGCTCAG 
-238-F CAGACGCGTCCCGCGCCAGTCCCTGCCG 
hSR-exon3-F ACCTTACGGGCTCTAGGAC 
hSR-intron4-R CCCCTGACCTTGTTCCGG 
Gel mobility shift assay 
NRSE-I ACCCTGCGCGGGGCGCTGAGCTC 
Non-specific GGCCACTAGAGGGAATTAAA 
rM4RE1 GGCTTCAGCACCTCGGAGAGCTCC 
shRNA construction 
NRSF-sh-top TACAGTTATGGCCACCCAGTTCAAGAGACTGGGTGGCCATAACTGTATTTTTT 
NRSF-sh-bottom AATTAAAAAATACAGTTATGGCCACCCAGTCTCTTGAACTGGGTGGCCATAAC
TGTAGGCC 
siControl-top TTCTTCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAATTTTTT 
siControl-bottom AATTAAAAAATTCTCCGAACGTGTCACGTTCTCTTGAAACGTGACACGTTCGG
AGAAGGCC 
Table 1 Oligonucleotide sequences. Sequences listed are from 5’ to 3’. The 
underlined regions of oligonucleotides for site-directed mutagenesis indicate the 
positions that carry mutations.  






